US FDA grants approval for Gilead’s Vemlidy to treat HBV infection
Pharmaceutical Technology
NOVEMBER 3, 2022
The US Food and Drug Administration (FDA) has granted approval for the supplemental new drug application (sNDA) of Gilead Sciences ’ Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) infection in paediatric patients.
Let's personalize your content